We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.78B
1-Year Est. Return 114.03%
This Fund
S&P 500
This Quarter Est. Return
+25.16%
1 Year Est. Return
+114.03%
3 Year Est. Return
+397.19%
5 Year Est. Return
+640.97%
10 Year Est. Return
+4,729.95%
AUM
$1.46B
AUM Growth
+$147M
Cap. Flow
-$82.7M
Cap. Flow %
-5.66%
Top 10 Hldgs %
25.13%
Holding
215
New
28
Increased
57
Reduced
41
Closed
25

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$31.1M
2
MRK icon
Merck
MRK
+$27.8M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$24.3M
4
IMGN
Immunogen Inc
IMGN
+$14.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$14.1M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$29.3M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$28.4M
3
UTHR icon
United Therapeutics
UTHR
+$26.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$25.8M
5
PODD icon
Insulet
PODD
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 53.92%
2 Technology 13.34%
3 Industrials 8.89%
4 Miscellaneous 5.77%
5 Consumer Discretionary 4.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
1
Krystal Biotech
KRYS
$10B
$44M 3.01%
374,951
+233
+0.1% +$23.8K
LEGN icon
2
Legend Biotech
LEGN
$3.42B
$40.9M 2.8%
593,167
-22,166
-4% -$1.45M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$37.8M 2.58%
414,419
+77,468
+23% +$6.68M
INSP icon
4
Inspire Medical Systems
INSP
$2.1B
$37.4M 2.56%
115,187
-3,671
-3% -$1.05M
ARGX icon
5
argenx
ARGX
$62.3B
$37.2M 2.54%
95,414
-23,211
-20% -$9.13M
ESTA icon
6
Establishment Labs
ESTA
$2.07B
$36.8M 2.51%
536,015
+79,531
+17% +$5.49M
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$35.7M 2.44%
928,637
-43,554
-4% -$1.12M
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$33.8M 2.31%
155,930
+108
+0.1% +$23.1K
SWAV
9
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$32.3M 2.21%
112,999
+92
+0.1% +$25.5K
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$31.6M 2.16%
+499,503
New +$31.1M
TMDX icon
11
Transmedics
TMDX
$3B
$30.9M 2.11%
367,631
+223
+0.1% +$17.1K
XENE icon
12
Xenon Pharmaceuticals
XENE
$5.55B
$30.5M 2.08%
791,118
+354,403
+81% +$14.1M
AXSM icon
13
Axsome Therapeutics
AXSM
$11.2B
$28.4M 1.94%
394,884
+54,454
+16% +$4.02M
MRK icon
14
Merck
MRK
$363B
$28.3M 1.93%
+244,934
New +$27.8M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$131B
$28.2M 1.93%
80,116
-10,175
-11% -$3.43M
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
$26.7M 1.83%
2,237,111
+633,721
+40% +$8.28M
VRNA
17
DELISTED
Verona Pharma
VRNA
$24.6M 1.68%
1,163,355
+222,055
+24% +$4.74M
MIRM icon
18
Mirum Pharmaceuticals
MIRM
$6.42B
$23.7M 1.62%
+915,119
New +$24.3M
IMGN
19
DELISTED
Immunogen Inc
IMGN
$23.1M 1.58%
+1,224,127
New +$14.5M
PCVX icon
20
Vaxcyte
PCVX
$8.98B
$23M 1.57%
460,164
+26,364
+6% +$1.25M
ROIV icon
21
Roivant Sciences
ROIV
$28.9B
$22.8M 1.56%
2,265,323
+1,192,940
+111% +$10.7M
LNTH icon
22
Lantheus
LNTH
$6.58B
$22.6M 1.55%
269,769
-108,336
-29% -$9.72M
CYTK icon
23
Cytokinetics
CYTK
$9.72B
$22.3M 1.52%
682,867
+71,877
+12% +$2.66M
MPWR icon
24
Monolithic Power Systems
MPWR
$57.5B
$19.5M 1.33%
36,047
-3,796
-10% -$1.8M
DICE
25
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$19.3M 1.32%
416,151
– –
1
2 3 4 5

Similar funds

FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.77B AUM 34.52% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.77B AUM 26.68% 1-Year Est. Return
WC
Waterloo Capital Austin, Texas $1.78B AUM 27.25% 1-Year Est. Return
IP
Indivisible Partners Clearwater, Florida $1.77B AUM
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return
SGAM
Stephens Group Asset Management Little Rock, Arkansas $1.77B AUM 17.59% 1-Year Est. Return
GWANC
Guardian Wealth Advisors (North Carolina) Raleigh, North Carolina $1.78B AUM 19.66% 1-Year Est. Return
CIA
Capital Impact Advisors Boston, Massachusetts $1.78B AUM 56.11% 1-Year Est. Return

Nicholas Investment Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Nicholas Investment Partners held 215 positions worth $1.46B, up 11% from $1.32B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Nicholas Investment Partners withdrew a net $82.7M in Q2 2023, closing 25 positions and reducing 41 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $29.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 53% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Intra-Cellular Therapies Inc. worth $31.6M.

  • Nicholas Investment Partners's largest Q2 2023 buy was Intra-Cellular Therapies Inc.: 499,503 shares worth $31.6M.
  • Nicholas Investment Partners added most to Xenon Pharmaceuticals in Q2 2023, an estimated $14.1M increase.
  • Nicholas Investment Partners's biggest Q2 2023 reduction was Lantheus, cutting an estimated $9.72M.
  • Nicholas Investment Partners fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $29.3M.
  • Nicholas Investment Partners's ten largest holdings make up 25% of its $1.46B portfolio in Q2 2023.
  • Nicholas Investment Partners opened 28 new positions and closed 25 in Q2 2023.
  • Nicholas Investment Partners's portfolio value rose 11% quarter-over-quarter to $1.46B.

Based on Nicholas Investment Partners's 13F filing for Q2 2023, filed 10 Aug 2023.